Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=558 HALT Progression of Polycystic Kidney Disease Study A
Kidney, Polycystic
Primary: Study A: Percent Annual Change in Total Kidney Volume — 6.0; 6.2; 5.6; 6.6 percentage of Total Kidney Volume — p=0.52
N/A N=36 A Multi-Center Study of Reading Rehabilitation in Macular Disease
Age Related Maculopathy · Retinal Degeneration
Primary: Sentence Reading — 58.9; 50.5; 86.2; 49.1 Words per Minute (wpm)
N/A N=40 Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)
Stroke
Primary: Completion of Clinical Follow-up as a Measure of Feasibility — 20; 18 participants
N/A N=309 Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice
Vertigo
Primary: Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE) — 43; 79; 104; 61 participants
N/A N=21 CNAP Accuracy in the Bariatric Surgery Population
Bariatric Surgery
Primary: The Absolute Difference in Mean Arterial Pressure Between the Arterial Catheter and the CNAP. — 7.7 mmHg
Phase 4 N=109 Efficacy of IV Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Sedation
Pain
Primary: Maximal Pain/Discomfort — 4.7; 4.3; 5.0 units on a scale
Phase 4 N=29 Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques
Atherosclerosis · Endothelial Function
Primary: Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS — 4; 6 participants
Phase 2 N=24 High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Safety Outcomes: Frequency of Adverse Events — 49; 24; 42 Total Number of Adverse Events — p=0.06
Phase 3 N=488 Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Kaplan-Meier Estimates for Overall Survival — 10.4; 6.5 months — p=0.0829
N/A N=698 Radial Artery Access With Ultrasound Trial
Coronary Artery Disease
Primary: Number of Attempts — 3.05; 1.65 forward attempts — p=<0.0001
N/A N=3,120 TeleQuit Smoking Cessation Program
Smoking
Primary: 7-day Point Prevalence Abstinence From Smoking — 21; 16.4; 16.9; 16.5 percentage of participants
Phase 4 N=32 Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel
Acne Vulgaris
Primary: Percentage of Participants Who Remained Responders at Week 24 — 82 percentage of particpants — p=<.0001
N/A N=40 Statin Therapy to Improve Atherosclerosis in HIV Patients
Cardiovascular Disease · HIV · Atherosclerosis
Primary: Coronary and Aortic Plaque Inflammation — 0.04; -0.05; -0.03; -0.06 ratio
N/A N=30 Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients
Idiopathic Scoliosis
Primary: Amplitude Required to Elicit the MEP — 307; 417 milliamperes